The collaboration was enabled by Atomwise’s AI Molecular Screen Awards program. AIMS gives academic researchers access to the same cutting-edge virtual drug screening technology used by large pharmaceutical companies, and also provides them with compounds for physical screening and expert guidance in structural biology and medicinal chemistry.
One of the chosen Michigan Medicine researchers will use Atomwise’s software to discover pain management drugs that could potentially replace opioids. Another will use the AI to develop a drug to inhibit growth of a fibrotic matrix, thus improving treatment options for fibrotic diseases of the lung, kidney and heart.
More articles about AI:
Machine learning predicts individual malaria outcomes, disease progression
Health tech consortium releases ethical guidelines for AI use in healthcare
Geisinger developing AI solutions to detect, prevent high-burden diseases
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.